Electrolyte Blood Press.  2011 Dec;9(2):50-54. 10.5049/EBP.2011.9.2.50.

V2 Receptor Antagonist; Tolvaptan

• Yi JH
• Shin HJ
• Kim HJ

• KMID: 2168384
• DOI: http://doi.org/10.5049/EBP.2011.9.2.50

Abstract

Hyponatremia is the most common electrolyte disorder in hospitalized patients. Many studies documented that it was related to increased morbidity and mortality in patients with congestive heart failure, liver cirrhosis, and neurologic diseases. Although knowledge of hyponatremia has been cumulated, the optimal management of hyponatremia remains incompletely established in clinical practice because of the diversity of underlying disease states, and its multiple causes with differing pathophysiologic mechanisms. Since vasopressin receptor antagonists have unique aquaretic effect to selectively increase electrolytes-free water excretion, clinicians could apply a more effective method to treat hyponatremia. Tolvaptan has significant evidence that it improves serum sodium levels in patients with euvolemic or hypervolemic hyponatremia related with heart failure, cirrhosis or syndrome of inappropriate anti-diuretic hormone. Tolvaptan has acceptable safety and tolerability for long-term usage in chronic hyponatremia, and the beneficial effects on serum Na+ occurred in patients with both mild and marked hyponatremia.

Keyword

tolvaptan; hyponatremia; arginine vasopressin receptors

MeSH Terms

Benzazepines
Fibrosis
Heart Failure
Humans
Hyponatremia
Liver Cirrhosis
Receptors, Vasopressin
Sodium
Water
Benzazepines
Receptors, Vasopressin
Sodium
Water

Reference

1. Verbalis JG. The syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders. Diseases of the kidney and urinary tract. 2007. 1st ed. Philadelphia: Lippincott Williams & Wilkins;p. 2214–2248.

2. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol. 2006; 17:1820–1832. PMID: 16738014.

3. Goldberg A, Hammerman H, Petcherski S, et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med. 2006; 166:781–786. PMID: 16606816.

4. De Luca L, Klein L, Udelson JE, et al. Hyponatremia in patients with heart failure. Am J Cardiol. 2005; 96:19L–23L.

5. Wu CC, Yeung LK, Tsai WS, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol. 2006; 65:28–33. PMID: 16429839.

6. Bhardwaj A. Neurological impact of vasopressin dysregulation and hyponatremia. Ann Neurol. 2006; 59:229–236. PMID: 16437573.

7. Guyton AC. The body fluids and kidneys. Textbook of medical physiology. 2006. Philadelphia (PA): WB Saunders Company;p. 291–414.

8. Brooks VL, Keil LC, Reid IA. Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs. Circ Res. 1986; 58:829–838. PMID: 3521934.

9. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol. 2002; 29:1–9. PMID: 12200224.

10. Lolait SJ, O'Carroll AM, Mahan LC, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A. 1995; 92:6783–6787. PMID: 7624319.

11. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol. 1999; 10:647–663. PMID: 10073616.

12. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992; 105:787–791. PMID: 1387020.

13. Samsca (tolvaptan tablets for oral use) [package insert]. 2009. Tokyo, Japan: Otsaka Pharmaceutical.

14. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists. Heart Fail Rev. 2009; 14:75–82. PMID: 18766438.

15. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008; 371:1624–1632. PMID: 18468546.

16. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355:2099–2112. PMID: 17105757.

17. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010; 21:705–712. PMID: 20185637.

18. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail. 2005; 11:260–269. PMID: 15880334.

19. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297:1319–1331. PMID: 17384437.

20. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007; 297:1332–1343. PMID: 17384438.